Note: before purchasing and taking medicines, a hospital genetic test report and a doctor's diagnosis report or certificate must be produced
Lenalidomide is used to treat some type of myelodysplastic syndrome (a group of conditions in which the bone marrow produces malformed blood cells and fails to produce enough healthy blood cells).
Lenalidomide is also used along with disaimisong for the treatment of multiple myeloma, a myeloid cancer
It is also used to treat patients with multiple myeloma after hematopoietic stem cell transplantation (HSCT; the process of removing some blood cells from and then returning to the body).
Lenalidomide is also used to treat mantle cell lymphoma (a rapidly growing cancer that begins with cells of the immune system) that has been treated with bortezomib (Velcade) and at least one other agent.
Lenalidomide should not be used to treat chronic lymphocytic leukemia (a white blood cell cancer that progressively worsens over time) unless they are enrolled in a clinical trial (investigational study to see if the drug can be safely and effectively used to treat a certain disease).
Lenalidomide is a drug called immunomodulator. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
After oral administration, the drug product is rapidly absorbed into the human body, and the elimination half-life is approximately in the order of 3 h.
The initiation of this medication is recommended to be 25 mg once daily for 28 days as one cycle, and patients taking medication need to be under the supervision and guidance of a physician and the dose of dexamethasone to be selected based on age. There is no experience dealing with this if overdose is said, but because the side effects are all hematologic in nature, prompt visits for treatment are indicated.
Patients were prohibited if they had abnormal values for neutrophil count, platelet count, and the proportion of plasma cells in the bone marrow that were nuclear.
Note: be sure to administer medication under the supervision of a doctor with relevant experience.
Medication specifications for special populations:
1.0-17 years for patients, not suitable for use;
2. The highest age of the population on the clinical trial was 86 years. Because elderly patients are likely to have decreased renal function and so on, it is imperative that such patients be monitored closely for renal function while on medication.
Patients who are pregnant or likely to be pregnant must not take lenalidomide. Lenalidomide is highly likely to cause severe birth defects (problems present at birth) or death of unborn infants.
Do not donate blood during lenalidomide administration, during treatment intervals, and within 4 weeks of the last dose.
Platelets as well as neutropenia are the most frequently present.
Other than that there are many symptoms like itching, rash, nausea, arthralgia, dyspnea, diarrhea, dizzy headache.
List or have problems clearly on the specification of this article.
1. Human birth defects, which, if taken by a pregnant woman, may lead to fetal defects or death;
2. There is a risk of hematological toxicities.